Annogen and Orchard Therapeutics join forces to develop CNS-specific promoters
In a significant move for gene therapy research, Annogen has announced a collaboration with Orchard Therapeutics to identify immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programmes. This partnership aims to advance the development of more targeted and potentially safer gene therapies for central nervous system (CNS) disorders.